Patients who use Libre CGM systems with their basal insulin therapy experienced:

• Lower A1C levels (1.1% reduction^§||5 in people with T2D)

The Libre 3 Plus sensor can help your patients monitor glucose levels in real time with automatic updates every minute. Plus, patients can set optional alarms^** that alert them the minute a threshold they set is crossed.

§ Study was performed with the US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.

|| Retrospective observational study with average baseline A1C 10.1% ± 1.7%.

** Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 20 feet (FreeStyle Libre 2) or 33 feet (FreeStyle Libre 3) unobstructed of the reading device.

Reference: 5. Wright, Eugene E. Jr., et al. “Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy.” Diabetes Spectrum 34, no. 2 (2021): 184–189. https://doi.org/10.2337/ds20-0069.

Yes. Libre systems help find hypoglycemic events that BGM is not identifying, notifying patients with optional alarms** the minute the threshold they set is crossed (eg, below 70 mg/dL).

** Alarm notifications will only be received when alarms settings are enabled and turned on and sensor is within 20 feet (FreeStyle Libre 2) or 33 feet (FreeStyle Libre 3) unobstructed of the reading device.

Patients using the Libre 3 Plus sensor saw reductions in A1C*⁸, hypoglycemia (38%*¹ and 43%*^#3 in people with T1D and T2D, respectively), and hospitalizations (66%*^††7).

* Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 2 and 3 systems, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.

# REPLACE Trial: A randomized, controlled trial to evaluate the impact of FreeStyle Libre glucose monitoring system (n=149) on HbA1C in people with T2D taking multiple daily doses of insulin at 6 months compared to blood glucose monitoring (BGM; n=75).

†† Reduction based on real-world data from 13.7% to 4.7% at 12 months (p<0.05).

References: 1. Bolinder, Jan, et al. “Novel Glucose-sensing Technology and Hypoglycaemia in Type 1 Diabetes: a Multicentre, Non-masked, Randomised Controlled Trial.” The Lancet 388, no. 10057 (2016): 2254–2263. https://doi.org/10.1016/S0140-6736(16)31535-5. 3. Haak, Thomas, et al. “Flash Glucose-sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial.” Diabetes Therapy 8, no. 1 (2017): 55–73. https://doi.org/10.1007/s13300-016-0223-6. 7. Fokkert, Marion, et al. “Improved Well-Being and Decreased Disease Burden After 1-Year Use of Flash Glucose Monitoring (FLARE-NL4).” BMJ Open Diabetes Research & Care 7, no. 1 (2019): e000809. https://doi.org/10.1136/bmjdrc-2019-000809. 8. Evans, Mark, Zöe Welsh, Sara Ells, and Alexander Seibold. “The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1C: a Meta-analysis of Clinical Trials and Real-world Observational Studies.” Diabetes Therapy 11, no. 1 (2020): 83–95. https://doi.org/10.1007/s13300-019-00720-0.

Yes. Patients using a GLP-1 therapy experienced significant improvement in A1C^† after initiating Libre systems, regardless of GLP-1 therapy duration or insulin type^‡4.

† 1.5 ± 1.9% (p<0.001).

‡ Real-world analysis of changes in A1C with the addition of FreeStyle Libre systems among adults with T2D currently using GLP-1 therapy (N=1,454).

Reference: 4. Miller, Eden, et al. “Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People With Sub‐optimally Treated Type 2 Diabetes Taking GLP‐1 RA Therapy.” Diabetes Therapy 15 (2024): 2027–2038. https://doi.org/10.1007/s13300-024-01619-1.

We understand that cost shouldn’t be a barrier for your patients with diabetes. In fact, our Libre 3 Plus sensor is the most affordable CGM available in pharmacies^‡‡9. If (commercially insured or uninsured) patients are asked to pay >$75 for two sensors, you can provide them with a Copay Card^§§.

Abbott provides this information as a courtesy and does not guarantee payment or coverage.

Coverage and out-of-pocket costs may vary based on your individual insurance plan. Please contact your insurance provider directly to confirm your specific benefits and eligibility.

‡‡ Based on pharmacy claims for the aggregate of patients covered by Commercial insurance, Managed Medicare, Managed Medicaid using the FreeStyle Libre personal CGM systems versus Dexcom CGM systems. Does not include fee-for-service Medicare or fee-for-service Medicaid. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

§§ Benefits apply to FreeStyle Libre 3 Plus sensors and FreeStyle Libre 3 readers. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured and uninsured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary.

Reference: 9. Data on file. Abbott Diabetes Care, Inc.